- Research article
- Open Access
Sharing genomic data from clinical testing with researchers: public survey of expectations of clinical genomic data management in Queensland, Australia
BMC Medical Ethics volume 21, Article number: 119 (2020)
There has been considerable investment and strategic planning to introduce genomic testing into Australia’s public health system. As more patients’ genomic data is being held by the public health system, there will be increased requests from researchers to access this data. It is important that public policy reflects public expectations for how genomic data that is generated from clinical tests is used. To inform public policy and discussions around genomic data sharing, we sought public opinions on using genomic data contained in medical records for research purposes in the Australian state of Queensland.
A total of 1494 participants completed an online questionnaire between February and May 2019. Participants were adults living in Australia. The questionnaire explored participant preferences for sharing genomic data or biological samples with researchers, and concerns about genomic data sharing.
Most participants wanted to be given the choice to have their genomic data from medical records used in research. Their expectations on whether and how often they needed to be approached for permission on using their genomic data, depended on whether the data was identifiable or anonymous. Their willingness to sharing data for research purposes depended on the type of information being shared, what type of research would be undertaken and who would be doing the research. Participants were most concerned with genomics data sharing that could lead to discrimination (insurance and employment), data being used for marketing, data security, or commercial use.
Most participants were willing to share their genomic data from medical records with researchers, as long as permission for use was sought. However, the existing policies related to this process in Queensland do not reflect participant expectations for how this is achieved, particularly with anonymous genomics data. This inconsistency may be addressed by process changes, such as inclusion of research in addition to clinical consent or general research data consent programs.
Australia is in the midst of a surge in public investment in clinical genomics through programs that focus on accelerated health service implementation and funding for translational research . In 2016, the Queensland State government committed $25 million to the accelerated implementation of genomics into public healthcare . Queensland has a population of approximately 5 million and a statewide public health system. The mainstreaming of genomics into Queensland’s clinical practice will result in an increasing amount of genomic data being held by the health system.
Australia’s public health system is predicated on patient health data, in both aggregated and individual forms, being used for research and quality improvement activities to enhance patient services and outcomes . In Queensland, there is legislation and associated policies that outline how and when health information can be used for research [4,5,6,7]. There are currently no specific policies related to sharing of clinically derived genomic data with researchers. Any application to access genomic data for research purposes is considered under the policies related to general health information [4, 5] and by Human Research Ethics Committees (HREC) using national standards .
In Queensland, anonymised health information can be shared with researchers for ethically approved projects without individual consent in circumstances where health information cannot be directly or indirectly linked back to the patient . Under certain circumstances, identifiable or re-identifiable health information can also be shared with researchers for ethically approved research . This can occur when: (a) the patient has provided specific consent to participate in the project, or (b) the Director General of Health, or his/her delegate, has approved a Public Health Act (PHA) application in circumstances where researchers are unable to obtain individual consent, or it is deemed inappropriate or practically infeasible to contact patients. When a PHA application is sought, the research project must fulfil a waiver of consent criteria stipulated in the National Statement on Ethical Conduct in Human Research .
There has been a number of international studies that looked at public, patient and research participant perspectives on various aspects of genomic data sharing. These studies inquired about trustworthiness, risk, sharing preferences and concerns [10,11,12,13,14,15]. Participant preference for sharing their genomic health information with researchers can differ due to jurisdictional, societal and demographic differences between study populations, and types of linkage to personal identifiers proposed for the study [10,11,12,13,14,15]. Recent work in Australia on health information and biospecimen sharing has observed an overall public willingness to participate in research [16,17,18]. This is caveated by differences of opinions in use of identifiable data [17, 18], the need to know who the data recipients are [16, 17], and a desire for autonomy in providing permission [16, 18].
This study explores public opinions related to the sharing of genomic data for research from clinical records in the context of current policies. Questions were framed around preferences relating to identifiable and anonymous genomic data or biological samples. The questionnaire was drafted in the context of current Queensland Health (QH) policies around data sharing for research purposes.
Eligible participants were adults aged 18 years or over who were residents of Australia, according to the postcode of residence provided. Recruitment was via a self-selected sampling strategy of the general population that utilised electronic direct marketing, QIMR Berghofer’s magazine (LifeLab), and social media posts on QIMR Berghofer’s Facebook and Twitter accounts. The electronic direct marketing contacted individuals who were on a QIMR Berghofer mailing list and who have previously subscribed to be notified about the Institute’s future research. The questionnaire was available online for 16 weeks from February 2019 to May 2019.
We surveyed both Queensland and non-Queensland residents. The participant groups from different states were included since: (1) there are cross jurisdictional agreements for the use of QH services by patients from different states, (2) residents from different states may have previously been residents of Queensland, and (3) some Queensland resident may not have experienced QH services. This questionnaire is based on a perception of QH and that perception can come from multiple sources that are not just based on personal experiences.
The cross-sectional online questionnaire (Additional file 1) comprised three sections: (A) socio-demographics, (B) permissions and preferences for either genomic data or biological samples sharing, and (C) concerns about genomic data sharing. The questionnaire contained 16 questions (Additional file 1: Section A: Q1–Q7, Section B: Q8–Q14, Section C: Q15–Q16) and took about 10–15 min to complete. Each section used a mixture of questions and answer formats including: single response, multiple responses, categorical responses, Likert scales, and open text box.
Questions related to permission for genomic data sharing were informed by the current QH policy on data sharing and consent (Q8–Q11) (Additional file 1). Questions related to preferences for genomic data sharing (Q12–Q14) are based on the categories and options used by the Australian Genomics Health Alliance CTRL platform for dynamic consent , which were derived from the Global Alliance for Genomic and Health’s Data Use Ontology technical standard . Response options provided for concerns about genomic data sharing were based on a previous international public survey [21, 22], and then modified for this study’s purpose based on feedback about comprehension from consumer representatives and expert community members from the Queensland Genomics Community Advisory Group (n = 11).
Participants were supplied with a definition of the terms identifiable and anonymous in the questionnaire. Identifiable was defined as “your genomic data or biological sample and your personal information (i.e. your name, date of birth or contact details)” and anonymous was defined as “information will be limited to your genomic data or biological sample only. Your personal information would not be linked to your genomics data or sample (i.e. your name, date of birth or contact details)” (Additional file 1). Depending on the genomic data set requested by researchers, these categories and the provided definitions are a simplification of the complexity of anonymising genomic data in practice. The choice of definitions provided was based on the terms used in QH data sharing policies  and testing of comprehension by community members.
For comparison of groups, the response categories of some demographics were grouped into fewer categories. Age was collapsed from the 10-year increments into three categories: 18–34 years, 35–54 years, or 55 years and over. Education was collapsed to university or non-university educated, while state to Queensland or non-Queensland based on postcode. Participants who were ‘unsure’ if they have had genetic or genomic testing were combined with those who answered ‘no’ to this question. For the gender demographic question, participants who selected ‘other’ were excluded from gender-based analysis due to the low number (n = 8), but were included in all other analyses. We categorised postcodes into areas of most disadvantaged to most advantaged using Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD) . SEIFA local government postcode list was also used to categorise postcodes to metropolitan or regional categories.
All statistical inference was conducted using available case analysis (i.e. only pairwise-complete participants were included for the chi-square tests). Categorical data was summarised using counts and percentages and compared using a chi-squared test. Statistical significance was set at p ≤ 0.01. Questions with multiple response options were dichotomised to allow for groupwise comparisons (Additional file 2). The open text response question (Q16) related to concerns was thematically analysed using a manual process. Analyses were conducted in Stata (version 15.1).
A total of 1658 participants started the questionnaire. After exclusion of those who did not respond after demographic questions (n = 161), and those either with international postcodes or without an identifiable Australian postcode (n = 3), there were 1494 responses that qualified for the analysis.
Participants ranged from 18 to over 75 years of age (Table 1). The majority of them were aged 55 years or more (71.4%, n = 1066), and female (66.8%, n = 994), while participants aged 18–35 years being under represented (3.9%, n = 58). Participants were disproportionally from higher socioeconomic status areas (combined ISRAD 3–5: 77.6%, n = 1143). The majority of participants were university educated (61.5%, n = 918) and almost one-third have worked in healthcare (31.8%, n = 473) (Table 1). Over half of participants were Queensland-based (55.6%, n = 820) as this was the target audience.
One-third of participants reported that they have had a genetic or genomics test in the past (29.2%, n = 435), which could have been clinical diagnostic test, participation in genomic research, or direct-to-consumer testing (health or recreational testing as defined previously ).
Permission for genomic data sharing
Overall, most agreed (86.2%, n = 1281) that QH should ask individual permission before sharing identifiable genomic data with researchers, but only one-third (35.7%, n = 530) considered individual permission necessary when sharing anonymous genomic data (Table 2).
Two-thirds nominated that QH should ask their permission either every time or sometime before their identifiable genomics data (68.6%, n = 1019) would be shared with researchers, with a further quarter preferring to be asked only the first time (26.3%, n = 391) (Table 2). For anonymous genomics data, preferences for being asked only once was higher (36.3%, n = 537) than the need to ask at least sometimes (25.7%, n = 380). There was little difference in the observed preferences for seeking permission for biological samples when compared with genomic data (Table 2).
Under half of all participants stated they would allow another person to give permission on their behalf, once they are no longer able to (43.1%, n = 642), with family members being the most preferred option (61.1%, n = 392), followed by nominated legal representative (e.g. power of attorney) (45.8%, n = 294) (Table 3).
Preferences for genomic data sharing
There were substantial variations in participant preferences for the organisations with which they would share their genomic data, ranging from 13.0 to 91.9% for anonymous and from 0.9 to 72.6% for identifiable data (Table 4). Overall, participants were between 12.1 and 31.1% less likely to share their identifiable than anonymous genomic data.
The majority of participants would share their genomic data with Australian not-for-profit organisations (Anonymous: 91.9%, n = 1361; Identifiable: 72.6%, n = 1076), or universities and research institutes (Anonymous: 91.8%, n = 1359; Identifiable: 71.6%, n = 1062) (Table 4).
Overseas governments (Anonymous: 17.1%, n = 247; Identifiable: 2.5%, n = 36), commercial companies (Anonymous: 17.1%, n = 247; Identifiable: 3.0%, n = 43) and data being made publically available (Anonymous: 13.0%, n = 187; Identifiable: 0.9%, n = 13) rated the lowest for sharing both anonymous and identifiable genomic data (Table 4).
Nearly all participants would agree to share anonymous genomic data for research of a condition they have (95.1%, n = 1407), other diseases or conditions (90.6%, n = 1341), or general public health research (86.7%, n = 1285). About half of all participants would share their anonymous genomic data for unspecified future research (48.9%, n = 717) (Table 4).
Concerns about genomic data sharing
The majority of participants expressed high concerns about potential insurance discrimination (83.8%, n = 1218), marketing companies (83.2%, n = 1211), employment based discrimination (80.7%, n = 1174), genomic data being made publically available (70.4%, n = 1026), stigmatisation (64.1%, n = 932), and ethnic/racial discrimination (63.0%, n = 912) (Table 5). In comparision, under one-fifth of participants felt the same high concern about family finding out about their health results (19.8%, n = 288), upsetting genetic relatives (19.9%, n = 290), or data being used for quality improvement in QH diagnostics (17.9%, n = 260).
The most common themes in the open text responses to concerns (n = 247) related to data security (22.3%, n = 55), commercial use or gains (13.4%, n = 33), autonomy in choosing to participate (10.9%, n = 27), and the use of genomic data without consent (10.1%, n = 25) (Table 6). Although the open text question intended to identify any other concerns about sharing genomic data from medical records for research, about 14.2% of respondants conveyed their support for sharing data for research purposes.
Comparing data sharing preferences across groups
Analyses based on demographic participant groups revealed some differences across the groups (Additional file 2). Participants who were < 55 years old, had worked in health care, or were university-educated indicated that the permission needed to be sought for the use of identifiable genomics data and this should occur more than once (p ≤ 0.01) (Additional file 2: Tables S1 and S2). Participants who did not reside in Queensland and were female indicated that permission should be required more than once for both identifiable genomic data and biological samples (p ≤ 0.01).
Participants who had previous experience with genetic testing, were ≥ 55 years or under 35 years old, or from Queensland more often agreed to sharing their anonymous genomic data for ancestry research (all p ≤ 0.01) (Additional file 2: Table S6). Conversely, participants who have worked in health care, in life sciences, or have attained university education less often agreeed to sharing genomics data for ancestry research or unspecified future research (p ≤ 0.01) (Additional file 2: Table S6). Preference for third party permission for use of anonymous genomics data varied depending on age, ISRAD at place of residence, education, and experience working in life science and with genetic testing (Additional file 2: Table S3). Participants preference for organisations that they would choose to share anonymous and identifiable genomics data varied between each of the demographic variables (p ≤ 0.01) (Additional file 2: Table S4 and S5).
A smaller proportion of Queensland residents and those with experience of genetic testing expressed high or moderate concern about sharing their genomic data compared to non-Queensland residents and those with no experience of genetic testing (Additional file 2: Table S7a and S7b).
Our questionnaire of public opinions of sharing genomic data from medical records found that participants were willing to share their genomic data with researchers. However, our results suggest that this willingness is predicated on several caveats related to; availability of personal details, organisation that will be the recipient, and type of research being undertaken. These results reflect the findings of previous studies related to health information and genomic data that have been observed in other public  and patients studies in Australia [17, 18]. Concerns about types of research related to topics with a higher level of ethical consideration, for example embryos and stem cells . Conversely, participants had high levels of support for using their genomic data in research of diseases they had, other diseases, or general population health. An important consideration is that unless ‘extended’ consent (as defined by National Statement ) for research into other disease and general population is collected in the clinical setting, there may be limitations in the ability to use anonymised genomics data for these research types without gaining individual consent. This is influenced by the National Statement  and HRECs applications of standards rather than QH policies.
In clinical genetic testing, there has been a debate surrounding the concept of genetic exceptionalism—which proposes that genetic and genomic data have special risks not observed in other types of health information and, therefore, needs different considerations in data management and patient consent . Participants in this study did not indicate genetic exceptionalism views, with similar preferences for data sharing for both biological samples and genomics data. Participants in a global study (that included Australians) who viewed genomic data as exceptional, were more willing to participate in research than those without genomic exceptionalism views , thus indicating that even if QH took a genomic exceptionalism position and developed genomic data specific policies, people would still participate in research. Perhaps this suggests that if any genomic data specific policy changes occur, they should occur in tandem with patient consent mechanisms for research.
Participant expectations for sharing and permissions are fundamentally different between anonymised and identifiable genomic data. This difference is reflected in health information sharing polices, but not to the extent expected by the study participants. The health information sharing policies of QH  largely reflect the opinions of the majority of participants when considered in the context of identifiable genomic data. In that, permission needs to be sought before using identifiable genomic data for research purposes. However, participants who want permission sought from a third party preferred family or legally nominated representatives to give consent when they are no longer able to consent, rather than data governance or HREC that are used in current policies.
In contrast, QH’s current policies around sharing of anonymous health information  do not reflect participant’s expectations in relation to genomic data. While one-third of participants would accept for their data to be used without permission for research uses, the majority would require permission to be sought at least once. There has been work within Australia to create a nationally consistent clinical genomic consent form that includes an option for participation in anonymised research . Implementation of research consent options into clinical consent forms could address this discrepancy between participant preferences and policy observed in this study.
In our analysis, age, educational, and work related factors were most commonly associated with differences in participant preferences for genomic data sharing. Specifically, those who were < 55 years old, university educated or worked in healthcare tended towards a reluctance to share their genomic data. Age, experience with poor health or genetic testing, and educational attainment have been identified as factors in both international and Australian studies of people’s willingness to share health information and genomic data with researchers or to participate in biobanking [10,11,12, 14, 16, 18, 22]. The association with age and educational attainment tend to vary depending on the location of survey participants [10,11,12, 16], whilst experience with genomics or poor health is consistently associated with a willingness to share with research [14, 18, 22]. In this study, experience of genetic testing did not influence preferences on whether and how often researchers need to seek permission for the use of genomic data (Additional file 1: S1 and S2), but these participants had less concern associated with sharing genomic data (Additional file 1: S7a and S7b). Residents of Queensland were less concerned with sharing of genomics data than respondents from other states, which reflects previous findings . Other studies have identified ethnicity/race and religiosity as influencing willingness to participate in genomic research [12, 27], which were not considered in this study.
The present study demonstrated apprehension for commercial organisations access genomic data for research that could be used for profit. This mistrust of for-profit companies has similarly been observed in studies based in other countries [10, 14]. Notably, participants stated they were more likely to give permission to have overseas research organisations (not-for-profit, medical institutes and universities) have access to their genomic data than the Australian government. This is in direct contrast to a study where research by domestic governments was shown to be preferred over international researchers .
Implications for insurance and employment were of particular concern for participants. Australia does not have specific genetic discrimination laws. Anti-discrimination legislations at both federal and state level are used for genetic discrimination cases [29, 30]. In Australia, individual health information is not used to determine private health insurance premiums . For life insurance, companies are limited in what genetic information a policy applicant is required to disclose. The limiting of disclosure requirements for life insurance has come about through a moratorium  rather than through legislation, and it is likely to change over time.
Based on open text responses to concerns, the desire to be asked permission seemed to stem from participants seeking autonomy over the ability to participate in research, wishing for their participation in research to reflect personal priorities and ethics, and a desire to know about the research in which they would be participating. Concerns over genomic data use outside of intended research did not limit participant’s willingness to participate in genomic research, which confirms the findings of other studies [10, 22]. Interestingly, some study participants conveyed a positive response to sharing data for research inspite of their concerns. Further exploration of the barriers and motivators to research participation would be useful to inform QH policies on clinical data sharing with research.
Policy directions and future work
The study highlights that current data sharing policies only partially reflect participant expectation on clinical genomic data sharing for research purposes. QH should explore policy or practice changes options, preferably with public consultation. This could be achieved through consultation with community, patient advocacy and advisory groups, which already exist within Queensland, or further research activities that engage specific groups. Surveys like this one set the scene for discussions, but are limited in granular details on what is a very complex topic.
There are groups within the population that are under-represented in this study and likely to require further engagement. In particular, the young (18–34 years), males, those with year 12 education or lower, and those living in lower socioeconomic areas. There are also populations that will need further consideration and engagement; patient groups, Aboriginal and Torres Strait Islanders communities, and cultural and linguistically diverse communities. Based on other work, these groups are likely to have different perspectives and expectations on sharing of clinical genomic data and biological samples for research purposes [11, 17, 33, 34].
To reflect participant expectations for genomic data management, not all changes need to be based on legislation and policy. They could also be addressed by documentation processes and programs. This study demonstrated that participants expect to be asked to share anonymous genomic data at least once. Mechanisms for ‘extended’ or ‘unspecified’ consent (as defined in National Statement ) could be included in clinical consent forms to provide an opt-in or opt-out option. A program within Australia has been working to standardise clinical consent for genomics, with clinical consent forms that include a research participation option . However, in the development of these clinical consent forms, there were opposing views about seeking research consent in clinical settings. Gaining consent to research from patients outside of a clinical setting or establishing ways for patients to have ongoing control of consent, such as dynamic consent platforms, could alleviate these concerns. In Queensland, there was a trial of gaining broad consent to research from patients outside of clinical consultations in the Giving InFormation To Research (GIFTR) program . Statewide application of a program like this may assist not only genomic research but other types of research as well. The options given will require ongoing investment, adjustment to consent wording in response to ethics guidance changes or legislative changes, and/or establishment of searchable information technology infrastructure to ensure current consent preferences can be applied.
The main limitation in the current study was there was a potential for bias due to over or under sampling of certain sub-populations of participants. Participants were predominantly females over 55 years in age and highly educated. This demographic spread is not representative of the general population . While a larger number of participants did enable us to consider responses of sub-populations, there is still the potential for bias due recruitment strategy and self-selection. These included the questionnaire only being available online, and recruitment material being primarily directed towards people with previous engagement with a research organisation. Both of which may lead to a biased sample of participants that is not representative of the general population. Based on the findings of other research [18, 22], we anticipated that a questionnaire of a patient group may produce different views on genomics data sharing for research purposes. Investigation of this group’s perspective is an essential next step in the genomic data sharing discussion.
Through the open text box questions some participants reported feeling concerns as questions (Q15–16) were ambiguous, as participants were not directed to consider an anonymous or identifiable scenario. As such, the findings related to concerns should be considered with caution. Genomics and its associated issues are technically difficult and multifaceted to explain, as such they do not lend themselves well to a multiple-choice based questionnaires as it is hard to convey nuanced opinions . In our questionnaire, participants were not given a definition of genomic data; therefore, responses were based on participant pre-existing understanding of genomic data, which we expect to vary greatly within the participants.
In the coming years, QH will be a repository for a large amount of clinically derived genomic data. With this, QH is likely to receive more requests from researchers to access this data using the existing data access practises and policies. This study indicates that, especially in the context of anonymous data, current policies may not meet participant expectation for autonomy in choosing how their clinical genomic data is shared with researchers. Further consultation is needed with demographic groups, including those that were under-represented in this study, patients, and populations with special cultural considerations, including Aboriginal and Torres Strait Islander communities, and culturally and logistically diverse communities.
This study demonstrates a high degree of variability in participants’ willingness and preferences for sharing their genomic data with researchers. Some health information management policies do not fulfil the expectation of participants for genomics data sharing. Here we propose process-driven changes, such as research consent during or after clinical consultation of anonymous genomic data use, as a way of better representing expectations for permission for data sharing. What is most important is that there is an active decision on genomic data management rather than a continuation of existing data sharing policies without review. This will assist in aligning public expectations with health policy directives, whilst also including global genomic policy developments, bioethics considerations, and technology advancements.
Availability of data and materials
The datasets generated and analysed during the current study are not publicly available because participants did not give consent to share the data beyond the research team.
Giving InFormation To Research
Human Research Ethics Committee
Index of Relative Socio-Economic Advantage and Disadvantage
Public Health Act
Queensland Genomics Health Alliance
Socio-Economic Indexes for Areas
Stark Z, Boughtwood T, Phillips P, Christodoulou J, Hansen DP, Braithwaite J, et al. Australian Genomics: a federated model for integrating genomics into healthcare. Am J Hum Genet. 2019;105(1):7–14.
Green Light for Genomics (Press Release). Brisbane: State of Queensland; 2016.
Innovation and Science Australia. Australia 2030: Prosperity Through Innovation. Canberra: Australian Government; 2017. https://www.industry.gov.au/sites/default/files/May%202018/document/pdf/australia-2030-prosperity-through-innovation-full-report.pdf.
Health Innovation Investment and Research Office. Access to Confidential Health Information: Queensland Health; 2019 [Updated 15 May 2019]. https://www.health.qld.gov.au/hiiro/html/regu/aces_conf_hth_info.
Privacy and Right to Information Unit. Privacy Plan. Brisbane: State of Queensland (Queensland Health); 2015. https://www.health.qld.gov.au/__data/assets/pdf_file/0027/439164/doh-privacy-plan.pdf.
Public Health Act 2005 (Queensland).
Information Privacy Act 2009 (Queensland).
National Health and Medical Research Council, Australian Research Council, Universities Australia. National Statement on Ethical Conduct in Human Research 2007 (Updated 2018). Canberra: Commonwealth of Australia; 2007.
Queensland Data Linkage Framework. State of Queensland (Queensland Health); 2016. https://www.health.qld.gov.au/__data/assets/pdf_file/0030/150798/qlddatalinkframework.pdf.
Trinidad SB, Fullerton SM, Bares JM, Jarvik GP, Larson EB, Burke W. Genomic research and wide data sharing: views of prospective participants. Genet Med. 2010;12(8):486–95.
Page SA, Manhas KP, Muruve DA. A survey of patient perspectives on the research use of health information and biospecimens. BMC Med Ethics. 2016;17(1):48.
Sanderson SC, Brothers KB, Mercaldo ND, Clayton EW, Antommaria AHM, Aufox SA, et al. Public attitudes toward consent and data sharing in biobank research: a large multi-site experimental survey in the US. Am J Hum Genet. 2017;100(3):414–27.
Kaufman DJ, Baker R, Milner LC, Devaney S, Hudson KL. A survey of US adults’ opinions about conduct of a nationwide precision medicine initiative cohort study of genes and environment. PLoS ONE. 2016;11(8):e0160461.
Goodman D, Johnson CO, Bowen D, Smith M, Wenzel L, Edwards K. De-identified genomic data sharing: the research participant perspective. J Commun Genet. 2017;8(3):173–81.
Jamal L, Sapp JC, Lewis K, Yanes T, Facio FM, Biesecker LG, et al. Research participants’ attitudes towards the confidentiality of genomic sequence information. Eur J Hum Genet. 2014;22(8):964–8.
King T, Brankovic L, Gillard P. Perspectives of Australian adults about protecting the privacy of their health information in statistical databases. Int J Med Inform. 2012;81(4):279–89.
Krahe M, Milligan E, Reilly S. Personal health information in research: perceived risk, trustworthiness and opinions from patients attending a tertiary healthcare facility. J Biomed Inform. 2019;95:103222.
Liddell J, Bain C, Myles PS. Patient and community attitudes toward perioperative biobanking and genomic research. Anaesth Intens Care. 2017;45(3):384–95.
Australian Genomic Health Alliance. CTRL—Managing your consent and participation in Australian Genomics research: Australian Genomic Health Alliance; 2019. https://www.australiangenomics.org.au/resources/for-patients/your-personal-platform/.
Global Alliance for Genomics and Health. Data Use Ontology approved as a GA4GH technical standard 2019. https://www.ga4gh.org/news/data-use-ontology-approved-as-a-ga4gh-technical-standard/.
Middleton A, Niemiec E, Prainsack B, Bobe J, Farley L, Steed C, et al. ‘Your DNA, Your Say’: global survey gathering attitudes toward genomics: design, delivery and methods. Pers Med. 2018;15(4):311–8.
Middleton A, Milne R, Howard H, Niemiec E, Robarts L, Critchley C, et al. Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic data. Eur J Hum Genet. 2020;28:424–34.
Statistics ABo. Technical Paper: Socio-Economic Indexes for Areas (SEIFA) 2016. Canberra: Commonwealth of Australia; 2018. https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258259000BA746/$File/SEIFA%202016%20Technical%20Paper.pdf.
Savard J, Hickerton C, Tytherleigh R, Terrill B, Turbitt E, Newson AJ, et al. Australians’ views and experience of personal genomic testing: survey findings from the Genioz study. Eur J Hum Genet. 2019;27(5):711–20.
Johnson S, Slade I, Giubilini A, Graham M. Rethinking the ethical principles of genomic medicine services. Eur J Hum Genet. 2019;28:147–54.
Australian Genomics Health Alliance. A National Approach to Clinical Consent for Genetic and Genomic Testing 2019 https://www.australiangenomics.org.au/resources/for-professionals/national-clinical-consent/.
Middleton A, Milne R, Thorogood A, Kleiderman E, Niemiec E, Prainsack B, et al. Attitudes of publics who are unwilling to donate DNA data for research. Eur J Med Genet. 2019;62(5):316–23.
Majumder MA, Cook-Deegan R, McGuire AL. Beyond our borders? Public resistance to global genomic data sharing. PLoS Biol. 2016;14(11):e2000206.
Anti-Discrimination Act 1991 (Queensland).
Australian Human Rights Commission Act 1986 (Commonwealth).
National Health and Medical Research Council. Genetic Discrimination. Canberra: Commonwealth of Australia; 2013.
Financial Services Council. FSC Standard No. 11: Moratorium on genetic tests in life insurance 2019. https://www.fsc.org.au/resources-category/standard/1779-standard-11-moratorium-on-genetic-tests-in-life-insurance/file.
Kowal E, Greenwood A, McWhirter RE. All in the blood: a review of Aboriginal Australians’ cultural beliefs about blood and implications for biospecimen research. J Empir Res Hum Res Ethics. 2015;10(4):347–59.
Mathew SS, Barwell J, Khan N, Lynch E, Parker M, Qureshi N. Inclusion of diverse populations in genomic research and health services: Genomix workshop report. J Commun Genet. 2017;8(4):267–73.
Health Informatics Society of Australia. HISA submission to Productivity Commission’s Inquiry into Data Availability and Use Canberra: Productivity Commission; 2016. https://www.pc.gov.au/__data/assets/pdf_file/0020/206813/sub199-data-access.pdf.
Australian Bureau of Statistics. 2016 Census QuickStats: Australia 2016. https://quickstats.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/036.
Milne R, Morley KI, Howard H, Niemiec E, Nicol D, Critchley C, et al. Trust in genomic data sharing among members of the general public in the UK, USA, Canada and Australia. Hum Genet. 2019;138:1237–46.
The authors would like to thank the QGHA Community Advisory Group, QGHA Ethical Social and Legal Implication program team, Medical Genomics and Genome Informatics labs at QIMR Berghofer, Matilda Haas and the Australian Genomics Health Alliance. Recruitment material and social media promotions were supported by QIMR Berghofer’s External Relations team.
This project was funded by Queensland Genomics Health Alliance (QGHA), Queensland Health, Queensland Government. NW is funded by a senior research fellowship (NHMRC, APP1139071).
Ethics approval and consent to participate
The study was approved by the QIMR Berghofer Human Research Ethics Committee (P3246). Approval was granted for the collection of anonymous data. Participants were provided with an online written information sheet prior to starting the online questionnaire. Undertaking the questionnaire was considered implied consent, a consent process approved for this study by the previously stated HREC in accordance with National Statement on Ethical Conduct in Human Research 2007 (Updated 2018), Section 2.2.5.
Consent for publication
MV, SK, EM and CH have no competing interests to declare. NW is co-founder, minor equity holder and Board member of genomiQa and a member of Queensland Genomics Community Advisory Group.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1.
Additional file 2.
Summary tables for statistical analysis of demographic groups.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Vidgen, M.E., Kaladharan, S., Malacova, E. et al. Sharing genomic data from clinical testing with researchers: public survey of expectations of clinical genomic data management in Queensland, Australia. BMC Med Ethics 21, 119 (2020). https://doi.org/10.1186/s12910-020-00563-6
- Public views
- Health information
- Data sharing
- Secondary use
- Data linkage